Triller and coworkers have investigated the impact of vanillin, as a TLR-2 inhibitor, to block the TLR2-mediated microglia pro-tumorigenic phenotype using in vitro and in situ microglia–glioma interaction experimental models [82]. The gene discussed is TLR2; the disease is central nervous system cancer.